Patient recruitment fully completed in OVM-200 Phase 1 trial

The Phase 1 trial of OVM-200, Oxford Vacmedix's lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was implemented

Oxford, UK – 17 June 2025

Oxford Vacmedix (OVM) announced today that patient recruitment in the ongoing Phase 1 trial of OVM-200 has been completed. 24 patients have been recruited in Phase 1b bringing the total recruitment, including Phase 1a, to 36 patients in the trial. All current patients in Phase 1b are being treated with new extended dosing of OVM-200, that was first suggested by the clinical investigators in the trial, following the excellent safety record seen in Phase 1a. The new regime allows up to 11 vaccinations of OVM-200 over a six-month period and has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). OVM-200 is a new cancer vaccine developed using OVM's novel recombinant overlapping peptide (ROP) platform. It targets survivin, a protein overexpressed by cancer cells, which prevents them being attacked by the body's immune system.

The Phase I trial of OVM-200 is focused on safety and on establishing an immune response in patients with three tumour types – non small cell lung cancer (NSCLC), prostate cancer and ovarian cancer. It is being run at four sites in the UK including the Sarah Cannon Institute and University College Hospital (UCH) in London, the Churchill hospital of the Oxford University Hospitals Foundation Trust (OUHFT) and the Christie NHS Foundation Trust in Manchester. The first part of the trial , Phase 1a, has been completed and has shown both excellent safety and a strong immune response. The Chief Investigator for the trial is Professor Martin Forster, based at UCH. This trial is the first time any ROP based vaccine has been tested in the clinic.

William Finch, CEO of Oxford Vacmedix, said:
"We are delighted to have completed recruitment in the OVM-200 Phase 1 trial in such a short time after implementing the extended dosing protocol. This demonstrates both confidence in our novel technology and the huge unmet need that there is for effective new immunotherapies. We look forward to seeing the results in these critically ill patients."

Professor Martin Foster, Chief Investigator at University College Hospital, London, added:
"We are very pleased to see the progress of the trial. The results from Phase 1a showed excellent safety and a strong immune response. We are hoping that extended dosing will produce a very durable immune response for our patients and maximise the potential benefits of this new form of immunotherapy."

ENDS

Oxford Vacmedix UK
The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK
T +44 (0)1865 742087 **E** enquiries@oxfordvacmedix.com www.oxfordvacmedix.com

For more information or to inquire about investing in Series B please contact:

William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742087 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com

Dr Nam Park, Chief Business Officer, Oxford Vacmedix
T: +44 (0)1865 742087 | M: +44(0)7904 613938 | E: npark@oxfordvacmedix.com

Notes to Editor

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford's Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Professor Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong immune response therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases.

The technology uses the novel, proprietary platform of ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases.

OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at head and neck and cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with IO agents.

OVM has recently secured the lead investment in Series B from Dx&Vx, a leading South Korean Pharma company, listed on KOSDAQ, and from existing shareholders in China. The company is currently seeking further Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination.

For more information: http://www.oxfordvacmedix.com